Premium
More than one angle to target aplastic anemia?
Author(s) -
Deeg H. Joachim
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31656
Subject(s) - medicine , eltrombopag , aplastic anemia , randomized controlled trial , anemia , bone marrow , platelet , immune thrombocytopenia
Eltrombopag has activity in treating aplastic anemia. The role of eltrombopag in first‐line therapy for aplastic anemia should be determined in a randomized prospective trial.